免疫治疗已成为当下恶性肿瘤治疗的基石.然而,不同患者对免疫治疗的反应具有较大异质性,并非都能从中获益.当下亟需寻找能高效预测免疫治疗疗效的生物标志物.C-C趋化因子配体4(C-Cchemokineligand 4,CCL4)是一种细胞因子,隶属于炎症性CCL亚家族,主要由免疫细胞、肿瘤细胞分泌,在正常组织中不表达或者弱表达,在多种恶性肿瘤组织中异常高表达.CCL4与其受体C-C趋化因子受体5(C-C chemokine receptor type 5,CCR5)结合后可招募并介导免疫细胞迁移,破坏肿瘤微环境(tumor micro environment,TME)的稳定性,参与致癌并促进肿瘤发展.在肿瘤免疫微环境中,CCL4可介导并募集单核细胞、巨噬细胞、自然杀伤(natural killer,NK)细胞、T细胞等关键免疫细胞定向迁移,成为影响免疫治疗疗效的潜在重要元素,而具有特定的价值.本文就CCL4在TME中影响免疫逃逸的研究进展进行综述,以期为基础研究及临床诊疗提供线索和参考.
Research Progresses on the Effects of CCL4 on Immune Escape in Tumor Microenvironment
Immunotherapy has become the cornerstone of current malignant tumor treatment.However,the response of different patients to immunotherapy is highly heterogeneous,and not all patients can benefit from it.There is an urgent need to find biomarkers that can effectively predict the efficacy of immunotherapy.C-C chemokine ligand 4(CCL4)is a cytokine,belonging to the inflammatory CCL subfamily.It is mainly secreted by immune cells and tumor cells and shows low or no expression in normal tissues but abnormally high expression in various malignant tumor tissues.After binding to CCL4 and its receptor C-C chemokine receptor type 5(CCR5),it can recruit and mediate immune cell migration,destroy the stabili-ty of the tumor microenvironment(TME),participate in carcinogenesis and promote the development of tumors.In the tumor immune microenvironment,CCL4 can mediate and recruit the directed migration of key immune cells such as monocytes,macrophages,natural killer(NK)cells,and T cells,which makes it a potentially important element affecting the efficacy of im-munotherapy and has specific value.This paper reviews the research progresses of CCL4's effects on immune escape in TME,in order to provide clues and references for basic research and clinical diagnosis and treatment.
万方数据
维普
